- Nachrichtendetail
-
16.04.2024 13:19:12 - dpa-AFX: Genmab's Q1 Darzalex Sales By Johnson & Johnson Reach $2.692 Bln
NEW BRUNSWICK (dpa-AFX) - Genmab A/S (GMAB), a Danish biotechnology firm,
announced on Tuesday that the first-quarter sales of Darzalex, Daratumumab, have
totaled $2.692 billion, as updated by Johnson & Johnson (JNJ).
Net trade sales were $1.464 billion in the U.S. and $1.228 billion in the rest
of the world.
Genmab is entitled to receive royalties on the sales of Darzalex, both the
intravenous and SC products, under the exclusive worldwide license to Janssen, a
subsidiary of Johnson & Johnson, to develop, make, and commercialize
Daratumumab.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
announced on Tuesday that the first-quarter sales of Darzalex, Daratumumab, have
totaled $2.692 billion, as updated by Johnson & Johnson (JNJ).
Net trade sales were $1.464 billion in the U.S. and $1.228 billion in the rest
of the world.
Genmab is entitled to receive royalties on the sales of Darzalex, both the
intravenous and SC products, under the exclusive worldwide license to Janssen, a
subsidiary of Johnson & Johnson, to develop, make, and commercialize
Daratumumab.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
JOHNSON + JOHNSON DL 1 | 853260 | Frankfurt | 136,500 | 29.04.24 19:07:38 | -0,500 | -0,36% | 0,000 | 0,000 | 137,000 | 137,000 |
